# Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

> **NCT04501120** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ascentage Pharma Group Inc.** · enrollment: 682 (estimated)

## Conditions studied

- Relapsed/Refractory Acute Myeloid Leukaemia
- Myeloid Malignancy

## Interventions

- **DRUG:** Lisaftoclax (APG-2575)
- **DRUG:** Reduced-dose HHT
- **DRUG:** standard-dose HHT
- **DRUG:** Azacitidine
- **DRUG:** Lisaftoclax (APG-2575)
- **DRUG:** olverembatinib

## Key facts

- **NCT ID:** NCT04501120
- **Lead sponsor:** Ascentage Pharma Group Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-09-28
- **Primary completion:** 2028-09
- **Final completion:** 2029-09
- **Target enrollment:** 682 (ESTIMATED)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04501120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04501120, "Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04501120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*